checkpoint inhibitor therapy

From Aaushi
Jump to navigation Jump to search

Indications

Adverse effects

Procedure

Mechanism of action

Comparative biology

More general terms

Additional terms

References

  1. 1.0 1.1 1.2 Komaroff AL Immunotherapy to Fight Cancer Begins to Work. NEJM Journal Watch. June 16, 2015 Massachusetts Medical Society (subscription needed) http://www.jwatch.org
    Sharma P and Allison JP. The future of immune checkpoint therapy. Science 2015 Apr 3; 348:56. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25838373
    Le DT et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015 May 30 PMID: https://www.ncbi.nlm.nih.gov/pubmed/26028255
  2. 2.0 2.1 2.2 Tucker ME Endocrinopathies Common With Checkpoint Immunotherapy for Cancer. American Association of Clinical Endocrinologists (AACE) 2017 Medscape. May 9, 2017 http://www.medscape.com/viewarticle/879727
  3. 3.0 3.1 3.2 3.3 Mager LF et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science 2020 Sep 18; 369:1481 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32792462 https://science.sciencemag.org/content/369/6510/1481
    Shaikh FY, Sears CL. Messengers from the microbiota. Science 2020 Sep 18; 369:1427 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32943510 https://science.sciencemag.org/content/369/6510/1427